...
首页> 外文期刊>Molecular and Cellular Endocrinology >Steroid receptor coactivators 1, 2, and 3: Critical regulators of nuclear receptor activity and steroid receptor modulator (SRM)-based cancer therapy
【24h】

Steroid receptor coactivators 1, 2, and 3: Critical regulators of nuclear receptor activity and steroid receptor modulator (SRM)-based cancer therapy

机译:类固醇受体共激活剂1、2和3:核受体活性和基于类固醇受体调节剂(SRM)的癌症治疗的关键调节剂

获取原文
获取原文并翻译 | 示例
           

摘要

Coactivators are a diverse group of non-DNA binding proteins that induce structural changes in agonist-bound nuclear receptors (NRs) that are essential for NR-mediated transcriptional activation. Once bound, coactivators function to bridge enhancer binding proteins to the general transcription machinery, as well as to recruit secondary coactivators that modify promoter and enhancer chromatin in a manner permissive for transcriptional activation. In the following review article, we focus on one of the most in-depth studied families of coactivators, the steroid receptor coactivators (SRC) 1,2, and 3. SRCs are widely implicated in NR-mediated diseases, especially in cancers, with the majority of studies focused on their roles in breast cancer. We highlight the relevant literature supporting the oncogenic activity of SRCs and their future as diagnostic and prognostic indicators. With much interest in the development of selective receptor modulators (SRMs), we focus on how these coactivators regulate the interactions between SRMs and their respective NRs; and, importantly, the influence that coactivators have on the functional output of SRMs. Furthermore, we speculate that coactivator-specific inhibitors could provide powerful, all-encompassing treatments that target multiple modes of oncogenic regulation in cancers resistant to typical anti-endocrine treatments.
机译:共激活因子是一组不同的非DNA结合蛋白,可诱导激动剂结合的核受体(NRs)发生结构变化,这对于NR介导的转录激活至关重要。一旦结合,共激活子就起到了将增强子结合蛋白桥接到通用转录机制的作用,并募集了次级共激活子,它们以允许转录激活的方式修饰了启动子和增强子染色质。在下面的评论文章中,我们重点研究最深入研究的共激活因子家族之一,类固醇受体共激活因子(SRC)1,2和3。SRC与NR介导的疾病(尤其是癌症)广泛相关大多数研究集中于它们在乳腺癌中的作用。我们重点介绍了支持SRC致癌活性的相关文献及其作为诊断和预后指标的未来。随着选择性受体调节剂(SRM)的发展,我们非常关注这些共激活因子如何调节SRM与它们各自的NR之间的相互作用。重要的是,共激活剂对SRM的功能输出具有影响。此外,我们推测,共激活因子特异性抑制剂可以提供强大的,全面的治疗方法,以针对典型抗内分泌治疗方法的癌症的多种致癌调控模式为目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号